{"id":"https://openalex.org/W2593675464","doi":"https://doi.org/10.1182/blood.v112.11.4265.4265","title":"The Vast Majority of CML-CP Patients Treated with Dasatinib (70 mg BID) Who Progress after Long-Term Follow-up (24 mo) Remain in Chronic-Phase","display_name":"The Vast Majority of CML-CP Patients Treated with Dasatinib (70 mg BID) Who Progress after Long-Term Follow-up (24 mo) Remain in Chronic-Phase","publication_year":2008,"publication_date":"2008-11-16","ids":{"openalex":"https://openalex.org/W2593675464","doi":"https://doi.org/10.1182/blood.v112.11.4265.4265","mag":"2593675464"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v112.11.4265.4265","doi":"https://doi.org/10.1182/blood.v112.11.4265.4265","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.4265.4265","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5015101485","display_name":"J\u00f6rge E. Cortes","orcid":"https://orcid.org/0000-0002-8636-1071","observed_orcids":["https://orcid.org/0000-0002-8636-1071"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jorge Cortes","raw_affiliation_strings":["M.D. Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M.D. Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015789771","display_name":"Michael J. Mauro","orcid":"https://orcid.org/0000-0002-2251-4032","observed_orcids":["https://orcid.org/0000-0002-2251-4032"]},"institutions":[{"id":"https://openalex.org/I165690674","display_name":"Oregon Health & Science University","ror":"https://ror.org/009avj582","country_code":"US","type":"education","lineage":["https://openalex.org/I165690674"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Mauro","raw_affiliation_strings":["Oregon Health & Science University, Portland, OR, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oregon Health & Science University, Portland, OR, USA","institution_ids":["https://openalex.org/I165690674"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102743501","display_name":"Susan Mary O'Brien","orcid":"https://orcid.org/0000-0003-3386-6540","observed_orcids":["https://orcid.org/0000-0003-3386-6540"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Susan O\u2019Brien","raw_affiliation_strings":["M.D. Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M.D. Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055045706","display_name":"Gautam M. Borthakur","orcid":"https://orcid.org/0000-0001-7679-6453","observed_orcids":["https://orcid.org/0000-0001-7679-6453"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gautam Borthakur","raw_affiliation_strings":["M.D. Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M.D. Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089428686","display_name":"William G. Wierda","orcid":"https://orcid.org/0000-0002-7357-270X","observed_orcids":["https://orcid.org/0000-0002-7357-270X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"William Wierda","raw_affiliation_strings":["M.D. Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M.D. Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034600739","display_name":"Yousif Matloub","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Yousif Matloub","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, CT, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055491299","display_name":"Ritwik Sinha","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ritwik Sinha","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, CT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, CT, USA","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"middle","author":{"id":null,"display_name":"David Liu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091812","display_name":"Bristol-Myers Squibb (United States)","ror":"https://ror.org/00gtmwv55","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091812"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"David Liu","raw_affiliation_strings":["Bristol-Myers Squibb, Wallingford, CT"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Bristol-Myers Squibb, Wallingford, CT","institution_ids":["https://openalex.org/I4210091812"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5090435894","display_name":"Hagop M. Kantarjian","orcid":"https://orcid.org/0000-0002-1908-3307","observed_orcids":["https://orcid.org/0000-0002-1908-3307"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hagop Kantarjian","raw_affiliation_strings":["M.D. Anderson Cancer Center, Houston, TX, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M.D. Anderson Cancer Center, Houston, TX, USA","institution_ids":["https://openalex.org/I1343551460"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.40608369,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":96},"biblio":{"volume":"112","issue":"11","first_page":"4265","last_page":"4265"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/dasatinib","display_name":"dasatinib","score":0.9390000104904175},{"id":"https://openalex.org/keywords/imatinib-resistance","display_name":"imatinib resistance","score":0.9390000104904175},{"id":"https://openalex.org/keywords/chronic-phase-cml","display_name":"chronic phase CML","score":0.7139999866485596},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.8069999814033508},{"id":"https://openalex.org/keywords/accelerated-phase-cml","display_name":"accelerated phase CML","score":0.8600000143051147},{"id":"https://openalex.org/keywords/blast-crisis","display_name":"blast crisis","score":0.8799999952316284},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.6880000233650208},{"id":"https://openalex.org/keywords/complete-cytogenetic-response","display_name":"complete cytogenetic response","score":0.7390000224113464},{"id":"https://openalex.org/keywords/complete-hematologic-response","display_name":"complete hematologic response","score":0.7590000033378601},{"id":"https://openalex.org/keywords/long-term-follow-up","display_name":"long-term follow-up","score":0.6349999904632568},{"id":"https://openalex.org/keywords/iris-trial","display_name":"IRIS trial","score":0.5490000247955322}],"concepts":[{"id":"https://openalex.org/C2779536868","wikidata":"https://www.wikidata.org/wiki/Q419940","display_name":"Dasatinib","level":4,"score":0.8678074479103088},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8182864189147949},{"id":"https://openalex.org/C2777583451","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib","level":3,"score":0.7569146156311035},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6961566209793091},{"id":"https://openalex.org/C3019892230","wikidata":"https://www.wikidata.org/wiki/Q177094","display_name":"Imatinib mesylate","level":4,"score":0.6631991863250732},{"id":"https://openalex.org/C2777413986","wikidata":"https://www.wikidata.org/wiki/Q412327","display_name":"Nilotinib","level":4,"score":0.5001428127288818},{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.43912506103515625},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.42455363273620605},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.4129566550254822},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.39183175563812256}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v112.11.4265.4265","doi":"https://doi.org/10.1182/blood.v112.11.4265.4265","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v112.11.4265.4265","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2561844337","https://openalex.org/W2565606062","https://openalex.org/W2027744772","https://openalex.org/W2552412286","https://openalex.org/W2242087004","https://openalex.org/W2566175026","https://openalex.org/W2281742031","https://openalex.org/W2160007211","https://openalex.org/W2323076980","https://openalex.org/W2339212443"],"abstract_inverted_index":{"Abstract":[0],"Patients":[1],"with":[2,36,103,213],"Chronic":[3],"Myeloid":[4],"Leukemia":[5],"(CML)":[6],"who":[7,73,119],"develop":[8],"resistance":[9],"to":[10,56,97,122,129,195,263,284,298,329,372],"imatinib":[11,23,47,82,162,285,328,359],"have":[12,120],"poor":[13],"clinical":[14,132,146],"outcomes.":[15],"The":[16,247],"disease":[17,159,225,268,344],"stage":[18],"at":[19,43,78,136,155,205],"the":[20,44,79,108,131,137,145,151,156,206,210,264,324,348],"time":[21,45,80,138,157],"of":[22,46,53,81,100,134,139,148,158,171,177,186,227,232,242,256,266,281,293,308,323,337],"failure":[24,83,368],"is":[25,114,127],"an":[26],"important":[27,128],"prognostic":[28],"factor":[29],"for":[30,110,216],"this":[31],"outcome.":[32],"Specifically,":[33],"although":[34],"patients":[35,72,101,118,135,149,212,250,271,295,351],"advanced-stage":[37],"CML,":[38,191],"particularly":[39],"those":[40,111],"in":[41,67,75,112,150,274,315,353,364],"blast-crisis":[42,309],"failure,":[48],"had":[49,223],"a":[50,277,320,334],"high":[51],"rate":[52],"cytogenetic":[54,179],"response":[55,174,180,283],"second-line":[57,87,304],"tyrosine":[58],"kinase":[59],"inhibitors":[60],"(TKIs),":[61],"these":[62],"responses":[63],"were":[64,203,261],"not":[65,313],"durable":[66],"most":[68,362],"instances.":[69],"In":[70,289,319],"contrast,":[71],"remained":[74,273,363],"chronic-phase":[76,113,275,365],"(CML-CP)":[77],"substantially":[84],"benefited":[85],"from":[86,374],"TKIs,":[88],"achieving":[89],"PFS":[90],"and":[91,163,269,286,303,340,360,369],"OS":[92],"that":[93,350],"appear":[94],"favorable":[95],"compared":[96],"historical":[98],"data":[99],"treated":[102],"non-TKI":[104],"therapeutic":[105,282,376],"modalities.":[106],"Because":[107],"prognosis":[109],"significantly":[115],"better":[116],"than":[117],"progressed":[121],"accelerated-":[123,187],"or":[124,188,192,279],"blast-phase,":[125],"it":[126],"examine":[130],"status":[133,147],"TKI":[140],"failure.":[141],"This":[142],"study":[143,317,355],"examined":[144],"START-C":[152],"trial":[153,326],"(CA180-013)":[154],"progression":[160,217,259],"after":[161,301,345,366],"dasatinib":[164,367],"therapy.":[165,305],"Progression":[166],"was":[167,311],"defined":[168,219],"as:":[169],"loss":[170,176,231,278],"complete":[172],"hematologic":[173],"(CHR),":[175],"major":[178],"(MCyR),":[181],"increasing":[182,236],"WBC":[183,237],"count,":[184],"development":[185,241,265,307],"blast-":[189],"phase":[190],"death":[193],"due":[194,262],"any":[196,214],"cause.":[197],"Of":[198,209],"387":[199],"participants,":[200],"322":[201],"(83%)":[202],"progression-free":[204],"2-year":[207],"follow-up.":[208],"65":[211,257],"criteria":[215],"as":[218,331],"above,":[220],"46":[221],"subjects":[222,338],"progressive":[224],"(loss":[226],"MCyR":[228],"=":[229,234,239,245],"14,":[230,235],"CHR":[233],"counts":[238],"8,":[240],"accelerated-phase":[243,299],"CML":[244,300,310],"10).":[246],"remaining":[248],"19":[249],"died.":[251],"Thus,":[252],"only":[253],"10":[254],"out":[255],"(15%)":[258],"events":[260],"advanced":[267],"36":[270],"(55%)":[272],"despite":[276],"lack":[280],"subsequent":[287],"dasatinib.":[288],"summary,":[290],"2.6%":[291],"(10/387)":[292],"all":[294],"analyzed":[296,352],"transitioned":[297],"first-":[302],"Importantly,":[306],"also":[312],"observed":[314],"our":[316,354],"population.":[318],"5-year":[321],"follow-up":[322],"IRIS":[325],"comparing":[327],"interferon":[330],"first-line":[332],"therapy,":[333],"projected":[335],"17%":[336],"relapsed":[339],"7%":[341],"developed":[342],"advanced-phase":[343],"imatinib.":[346],"Despite":[347],"fact":[349],"sequentially":[356],"failed":[357],"both":[358],"dasatinib,":[361],"are":[370],"expected":[371],"benefit":[373],"additional":[375],"options.":[377]},"counts_by_year":[{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-03-16T00:00:00"}